The Role of Pharmacological Thromboprophylaxis in Preventing Venous Thromboembolism in Acutely Ill Medical Patients: A Review of Landmark Trial Evidence

Abstract

Introduction: Hospitalized, acutely ill medical patients face a significant risk of venous thromboembolism (VTE), a major cause of preventable hospital-acquired morbidity and mortality. For many years, the routine use of pharmacological prophylaxis in this broad and heterogeneous population was not a universal standard of care, owing to a lack of definitive evidence.

Literature Review: A review of pivotal literature reveals a series of large-scale, randomized, placebo-controlled trials that decisively established the benefit of thromboprophylaxis. Landmark studies such as the PREVENT trial demonstrated that prophylactic doses of low-molecular-weight heparin (LMWH) significantly reduced the incidence of VTE, including proximal deep vein thrombosis and pulmonary embolism, compared to placebo. The ARTEMIS trial subsequently confirmed this benefit using the synthetic Factor Xa inhibitor, fondaparinux. This substantial reduction in thrombotic events was achieved with an acceptable safety profile, without a significant increase in major bleeding complications. This body of high-quality evidence prompted the development of risk assessment models and the widespread adoption of routine VTE prophylaxis for at-risk medical patients into major international clinical practice guidelines.

Conclusion: The evidence reviewed established pharmacological thromboprophylaxis as a safe, effective, and essential intervention for at-risk medical inpatients. This research transformed the standard of care, making VTE prevention a fundamental component of patient safety and hospital quality improvement initiatives worldwide.